Product Information
INVEGA TRINZA 273 MG/0.88 ML is a brand product labeled by Janssen Pharmaceuticals Inc., priced at $3950.9489 per ML under NDC 50458060601. Its NADAC has been published 102 times since Oct 23, 2024.
FDA first approved this application on May 18, 2015.
Strength
273 mg/.88mL
Manufacturer
Janssen Pharmaceuticals Inc.NDC
50458060601
Classification
Brand
Dosage Form
INJECTION, SUSPENSION, EXTENDED RELEASE
Route
INTRAMUSCULAR
Effective Date
9/23/2026
Active Ingredients
PALIPERIDONE PALMITATEApproval Type
New Drug (NDA)
FDA Application
NDA207946FDA Approved
5/18/2015
On Market Since
5/19/2015
Pharmacological Classes
Price Statistics
The NADAC for INVEGA TRINZA 273 MG/0.88 ML has been published 102 times since Oct 23, 2024, and over the history we have for it it has risen 3.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3950.9489 per ML |
|---|---|
| All-time high | $3988.8369 (Jul 15, 2026) |
| All-time low | $3807.1364 (Dec 18, 2024) |
| 52-week high | $3988.8369 |
| 52-week low | $3886.4332 |
| Median price | $3906.1219 |
| Average price | $3917.4139 |
| Largest weekly change | +2.6% (Jan 15, 2025) |
| Weeks tracked | 102 |
| Tracking since | Oct 23, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the paliperidone palmitate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Janssen Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
paliperidone palmitate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INVEGA TRINZA 273 MG/0.88 ML?
The current National Average Drug Acquisition Cost (NADAC) for INVEGA TRINZA 273 MG/0.88 ML, manufactured by Janssen Pharmaceuticals Inc., is $3950.9489 per ML (NDC 50458060601), effective Sep 30, 2026.
How has the price of INVEGA TRINZA 273 MG/0.88 ML changed over time?
Over the history we have for it, the NADAC for INVEGA TRINZA 273 MG/0.88 ML has risen 3.6%. It has been tracked across 102 weekly CMS publications since Oct 23, 2024.
What are the highest and lowest recorded NADAC prices for INVEGA TRINZA 273 MG/0.88 ML?
Since Oct 23, 2024, the NADAC for INVEGA TRINZA 273 MG/0.88 ML has ranged from a low of $3807.1364 (Dec 18, 2024) to a high of $3988.8369 (Jul 15, 2026), with a median of $3906.1219 per ML.
Are there cheaper alternatives to INVEGA TRINZA 273 MG/0.88 ML?
No other NADAC-published product currently shares the active ingredient and strength of INVEGA TRINZA 273 MG/0.88 ML in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures INVEGA TRINZA 273 MG/0.88 ML?
INVEGA TRINZA 273 MG/0.88 ML (NDC 50458060601) is labeled by Janssen Pharmaceuticals Inc., and CMS classifies it as a brand product.